HOTH News and Press, Hoth Therapeutics Inc. From 03/17/21

Hoth Therapeutics (HOTH) announces entering into a Research Agreement with the University of Cincinnati Research Institute ("UCRI") to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.HT-006 is a novel antibiot...

Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006 PR Newswire NEW YORK , March 17, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical ...

Microcap Hoth Therapeutics (HOTH) has signed an agreement with contract research organization REPROCELL Ltd. to evaluate the HT-003 platform on tissue from ulcerative colitis and Crohn's patients.Hoth says that HT-003's active pharmaceutical ingredient is an inhibitor of retinoic acid metabol...

Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease PR Newswire NEW YORK , March 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, ...

Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Hoth's Largest Shareholder Agrees to One Year Lockup PR Newswire NEW YORK , March 10, 2021 /PRNewswire/ -- Hoth Therapeutics, I...

ACADIA Pharmaceuticals (ACAD) -45% after suffers setback in label expansion application for Pimavanserin.Stitch Fix (SFIX) -22% on FQ2 earnings release.Waitr Holdings (WTRH) -16% on Q4 earnings release.DICK'S Sporting Goods (DKS) -6% on Q4 earnings rele...

Hoth Therapeutics (HOTH) inks securities purchase agreement with institutional investors to raise capital through issuance of an ~7.59M common shares at $1.975/share, in a private placement priced at-the-market.Additionally, warrants to purchase of ~7.59M shares at exercise price of $1.8...

Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire NEW YORK , March 8, 2021 /PRNewswire/ --  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today...

Hoth Therapeutics (HOTH) provides an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19. There are three leading peptide candidates that have been optimized chemically to maximize the potential viral inhibition.One of the peptide candidates ha...

Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies Analysis supports that these optimized peptides could be effective against the emerging UK and South African SARS-CoV-2 strain variants PR Newswire NEW YORK , Mar...